Immunetrics, Inc. Extends In Silico Modeling Collaboration With Eli Lilly and Company (LLY)  
8/30/2006 10:25:22 AM

PITTSBURGH, Aug. 30 /PRNewswire/ -- Immunetrics Inc. has extended its collaboration with Eli Lilly and Company in the application of in silico modeling technology to clinical trial design.

The collaboration expands on a previously announced project in which the companies sought to validate the use of Immunetrics in silico models of inflammation in predicting the outcomes of clinical trials and in optimizing the design of a clinical study. Following this successful demonstration, the further collaboration will expand the scope of clinical trial design activity.

Certain results of the initial collaboration were jointly presented by Immunetrics and Lilly at the June 2006 conference of the Shock Society. The presentation described the development of a system of nonlinear differential equations describing the time course of immune response and coagulation in sepsis, including the effects of trauma and surgery. The trial simulation involved cohorts of large numbers of genetically diverse "virtual" patients. While a typical simulated trial size involved 40,000 subjects, the total number of subjects simulated over the course of the initial collaboration exceeded 1.4 million.

The model was used to predict the outcome of a Phase 3B study of Xigris(R) in sepsis. The simulated clinical trial predicted 28-day mortality well within the limits of statistical error. The simulated clinical trial also accurately predicted the actual results in most subgroups divided according to age and the presence or absence of surgery. The companies' joint Shock presentation poster may be viewed at

About Immunetrics Inc.

Immunetrics is a Pittsburgh-based biosimulation company providing a platform to model complex biological systems. Immunetrics possesses the first known comprehensive model of the inflammatory response. With the ability to model any major biological phenomena, to date it has expanded its suite of models to include adaptive immunity, the coagulation cascade and the arachidonic acid cascade. With these models, Immunetrics helps drug companies identify clinically relevant predictive biomarkers and prioritize and design preclinical and clinical studies. Immunetrics was founded by LaunchCyte LLC and has been funded by Innovation Works, the University of Pittsburgh Medical Center, the University of Pittsburgh, the Pittsburgh Life Sciences Greenhouse, and individual investors.

Immunetrics Inc.

CONTACT: Steven Chang, Chief Executive Officer of Immunetrics Inc.,+1-412-770-1311, or